Gastrointestinal Tract Cancer - Pipeline Review, H2 2012

Description: Gastrointestinal Tract Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Gastrointestinal Tract Cancer - Pipeline Review, Global Markets Direct's, 'Gastrointestinal Tract Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Tract Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Tract Cancer. Gastrointestinal Tract Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastrointestinal Tract Cancer.
- A review of the Gastrointestinal Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gastrointestinal Tract Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Tract Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Tract Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
</tr>
<tr>
<td>List of Tables 15</td>
</tr>
<tr>
<td>List of Figures 22</td>
</tr>
<tr>
<td>Introduction 23</td>
</tr>
<tr>
<td>REPORT COVERAGE 23</td>
</tr>
<tr>
<td>Gastrointestinal Tract Cancer Overview 24</td>
</tr>
<tr>
<td>Therapeutics Development 25</td>
</tr>
<tr>
<td>An Overview of Pipeline Products for Gastrointestinal Tract Cancer 25</td>
</tr>
<tr>
<td>Gastrointestinal Tract Cancer Therapeutics under Development by Companies 27</td>
</tr>
<tr>
<td>Gastrointestinal Tract Cancer Therapeutics under Investigation by Universities/Institutes 41</td>
</tr>
</tbody>
</table>
Late Stage Products 60
Comparative Analysis 60
Mid Clinical Stage Products 61
Comparative Analysis 61
Early Clinical Stage Products 62
Comparative Analysis 62
Discovery and Pre-Clinical Stage Products 63
Comparative Analysis 63
Gastrointestinal Tract Cancer Therapeutics – Products under Development by Companies 64
Gastrointestinal Tract Cancer Therapeutics – Products under Investigation by Universities/Institutes 81
Companies Involved in Gastrointestinal Tract Cancer Therapeutics Development 129
Bristol-Myers Squibb Company 129
Johnson & Johnson 130
F. Hoffmann-La Roche Ltd. 131
Shionogi & Co., Ltd. 132
Amgen Inc. 133
Sanofi-Aventis 134
AstraZeneca PLC 135
Eli Lilly and Company 136
Viralytics Ltd. 137
GlaxoSmithKline plc 138
Tekmira Pharmaceuticals Corp. 139
Genentech, Inc. 140
Nektar Therapeutics 141
Inovio Biomedical Corporation 142
Bavarian Nordic A/S 143
Daichi Sankyo Company, Ltd 144
AbGenomics International, Inc. 145
Oxford BioMedica plc 146
Infinity Pharmaceuticals, Inc. 147
YM BioSciences Inc. 148
FibroGen, Inc. 149
Light Sciences Oncology, Inc. 150
Panaceo Pharmaceuticals, Inc. 151
Piramal Healthcare Limited 152
MediGene AG 153
BioSante Pharmaceuticals, Inc. 154
ZIOPHARM Oncology, Inc. 155
Millennium Pharmaceuticals, Inc. 156
Novartis AG 157
Samyang Corporation 158
Aphios Corporation 159
Astellas Pharma Inc. 160
QS1 Pharmaceuticals, Inc. 161
SuperGen, Inc. 162
Taiho Pharmaceutical Co., Ltd. 163
Yakult Honsha Co., Ltd. 164
Zeria Pharmaceutical Co Ltd 165
Cell Therapeutics, Inc. 166
Exelixis, Inc. 167
Aduro BioTech 168
Incyte Corporation 169
Halozyme Therapeutics 170
Merck KGaA 171
Access Pharmaceuticals, Inc. 172
Advaxis, Inc. 173
Neogenix Oncology Corporation 174
EntreMed, Inc. 175
Momenta Pharmaceuticals, Inc. 176
Anavex Life Sciences Corp. 177
ValiRx Plc 178
ImmunCellular Therapeutics, Ltd. 179
IMMUNOMEDICS, INC 180
Bristol-Myers Squibb Company, H2 2012 129
Johnson & Johnson, H2 2012 130
F. Hoffmann-La Roche Ltd., H2 2012 131
Shionogi & Co., Ltd., H2 2012 132
Amgen Inc., H2 2012 133
Sanofi-Aventis, H2 2012 134
AstraZeneca PLC, H2 2012 135
Eli Lilly and Company, H2 2012 136
Viralytics Ltd., H2 2012 137
GlaxoSmithKline plc, H2 2012 138
Tekmira Pharmaceuticals Corp., H2 2012 139
Genentech, Inc., H2 2012 140
Nektar Therapeutics, H2 2012 141
Inovio Biomedical Corporation, H2 2012 142
Bavarian Nordic A/S, H2 2012 143
Daichi Sankyo Company, Ltd, H2 2012 144
Oxford BioMedica plc, H2 2012 146
Infinity Pharmaceuticals, Inc., H2 2012 147
YM BioSciences Inc., H2 2012 148
FibroGen, Inc., H2 2012 149
Light Sciences Oncology, Inc., H2 2012 150
Panacea Pharmaceuticals, Inc., H2 2012 151
Piramal Healthcare Limited, H2 2012 152
MediGene AG, H2 2012 153
BioSante Pharmaceuticals, Inc., H2 2012 154
ZIOPHARM Oncology, Inc., H2 2012 155
Millennium Pharmaceuticals, Inc., H2 2012 156
Novartis AG, H2 2012 157
Samyang Corporation, H2 2012 158
Aphiios Corporation, H2 2012 159
Astellas Pharma Inc., H2 2012 160
OSI Pharmaceuticals, Inc., H2 2012 161
SuperGen, Inc., H2 2012 162
Taiho Pharmaceutical Co., Ltd., H2 2012 163
Yakult Honsha Co., Ltd., H2 2012 164
Zeria Pharmaceutical Co Ltd, H2 2012 165
Cell Therapeutics, Inc., H2 2012 166
Exelixis, Inc., H2 2012 167
Aduro BioTech, H2 2012 168
Incyte Corporation, H2 2012 169
Haloxyne Therapeutics, H2 2012 170
Merck KGaA, H2 2012 171
Access Pharmaceuticals, Inc., H2 2012 172
Advaxis, Inc., H2 2012 173
Neogenix Oncology Corporation, H2 2012 174
Entremed, Inc., H2 2012 175
Momenta Pharmaceuticals, Inc., H2 2012 176
Anavex Life Sciences Corp., H2 2012 177
Valirx Plc, H2 2012 178
ImmunoCellular Therapeutics, Ltd., H2 2012 179
IMMUNOMEDICS, INC, H2 2012 180
Karo Bio, H2 2012 181
Lorus Therapeutics Inc, H2 2012 182
MethylGene Inc, H2 2012 184
Molecular Insight Pharmaceuticals, Inc., H2 2012 185
Northwest Biotherapeutics, Inc., H2 2012 186
Oncolytics Biotech Inc., H2 2012 187
Peregrine Pharmaceuticals, Inc., H2 2012 188
Critical Outcome Technologies Inc., H2 2012 189
La Jolla Pharmaceutical Company, H2 2012 190
Bionovo, Inc., H2 2012 191
Telik, Inc., H2 2012 192
Champions Biotechnology, Inc., H2 2012 193
Pharmacyclics, Inc., H2 2012 194
ProMetic Life Sciences Inc., H2 2012 195
Green Cross Corporation, H2 2012 196
Innocell Corporation, H2 2012 197
OncoTherapy Science, Inc., H2 2012 198
Quest PharmaTech Inc., H2 2012 199
Threshold Pharmaceuticals, Inc., H2 2012 200
Synta Pharmaceuticals Corp., H2 2012 201
BioAlliance Pharma SA, H2 2012 202
Natco Pharma Limited, H2 2012 203
Sareum Holdings plc, H2 2012 204
Simcere Pharmaceutical Group, H2 2012 205
Transgene Biotek Ltd, H2 2012 206
Rexahn Pharmaceuticals, Inc., H2 2012 207
Mabvax Therapeutics, Inc., H2 2012 208
Morphotek, Inc., H2 2012 209
D-Pharm Ltd., H2 2012 210
Antisense Pharma GmbH, H2 2012 211
Avanti Therapeutics, H2 2012 212
Wilex AG, H2 2012 213
Supratek Pharma Inc., H2 2012 214
Immupharma Plc, H2 2012 215
GANYMED Pharmaceuticals AG, H2 2012 216
Phloogen S.p.A., H2 2012 217
Multimmune GmbH, H2 2012 218
Nerviano Medical Sciences S.r.l., H2 2012 219
Wellstat Therapeutics Corporation, H2 2012 220
Hutchison MediPharma Limited, H2 2012 221
ERYtech Pharma, H2 2012 222
Advantagene, Inc., H2 2012 223
Provecs Medical GmbH, H2 2012 224
Alethia Biotherapeutics Inc., H2 2012 225
Ascenta Therapeutics, Inc., H2 2012 226
Gene Signal International SA., H2 2012 227
Heat Biologics, Inc., H2 2012 228
MacroGenics, Inc., H2 2012 229
Antyra, Inc., H2 2012 230
TetraLogic Pharmaceuticals, H2 2012 231
Celecure AS, H2 2012 232
Azaya Therapeutics, Inc., H2 2012 233
Merrimack Pharmaceuticals, Inc., H2 2012 234
RESprotect GmbH, H2 2012 235
ProNai Therapeutics, Inc., H2 2012 236
Jennenerex Biotherapeutics, Inc., H2 2012 237
Stemline Therapeutics, Inc., H2 2012 238
Axcentua Pharmaceuticals AB, H2 2012 239
BioCancell Therapeutics, Inc., H2 2012 240
Cornerstone Pharmaceuticals, Inc., H2 2012 241
Pharminox Limited, H2 2012 242
PhytoCeutica, Inc., H2 2012 243
Myriad Pharmaceuticals, Inc., H2 2012 244
KangLaiTe USA, H2 2012 245
NovaLead Pharma Pvt. Ltd., H2 2012 246
Esperance Pharmaceuticals, Inc., H2 2012 247
Omeros Corporation, H2 2012 248
Transtech Pharma, Inc., H2 2012 249
Welichem Biotech Inc., H2 2012 250
Oncolys BioPharma Inc., H2 2012 251
Globeimmune, Inc., H2 2012 252
NewLink Genetics Corporation, H2 2012 253
Tragara Pharmaceuticals, Inc., H2 2012 254
Cellceutix Corporation, H2 2012 255
PharmaMar, S.A., H2 2012 256
Quintessence Biosciences, Inc., H2 2012 257
Tigris Pharmaceuticals, Inc., H2 2012 258
Lipopharma, H2 2012 259
Nereus Pharmaceuticals, Inc., H2 2012 260
AVEO Pharmaceuticals, Inc., H2 2012 261
Kringle Pharma, Inc., H2 2012 262
Medisyn Technologies, Inc., H2 2012 263
Keystone Nano, Inc., H2 2012 264
Perseus Proteomics, Inc., H2 2012 265
Pique Therapeutics, H2 2012 266
Cancer Therapeutics CRC Pty Ltd, H2 2012 267
Eleison Pharmaceuticals, Inc., H2 2012 268
Targa Therapeutics Corp., H2 2012 269
ImmunoFrontier, Inc., H2 2012 270
NuCana BioMed Limited, H2 2012 271
KAEL-GemVax, H2 2012 272
iCeutica, Inc., H2 2012 273
Mebiopharm Co., Ltd., H2 2012 274
Polaris Group, H2 2012 275
Eurofarma, H2 2012 276
DEKK-TEC, Inc., H2 2012 277
IkerChem S.L., H2 2012 278
Theradex Systems, Inc., H2 2012 279
Regulon Inc., H2 2012 280
TAU Therapeutics, LLC, H2 2012 281
FunZyme BioTechnologies S.A., H2 2012 282
Epeius Biotechnologies Corporation, H2 2012 283
Oncozyme Pharma Inc., H2 2012 284
Biotech Pharmaceuticals Co., Ltd., H2 2012 285
CytomX, LLC., H2 2012 286
Assessment by Monotherapy Products, H2 2012 287
Assessment by Combination Products, H2 2012 288
Assessment by Stage and Route of Administration, H2 2012 290
Assessment by Stage and Molecule Type, H2 2012 292
Gastrointestinal Tract Cancer Therapeutics – Drug Profile Updates 426
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products 431
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..1) 432
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..2) 433
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..3) 434
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..4) 435
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..5) 436
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..6) 437
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..7) 438
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..8) 439
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..9) 440
Gastrointestinal Tract Cancer Therapeutics – Discontinued Products (Contd..10) 441
Gastrointestinal Tract Cancer Therapeutics – Dormant Products 442
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..1) 443
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..2) 444
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..3) 445
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..4) 446
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..5) 447
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..6) 448
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..7) 449
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..8) 450
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..9) 451
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..10) 452
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..11) 453
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..12) 454
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..13) 455
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..14) 456
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..15) 457
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..16) 458
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..17) 459
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..18) 460
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..19) 461
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..20) 462
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..21) 463
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..22) 464
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..23) 465
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..24) 466
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..25) 467
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..26) 468
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..27) 469
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..28) 470
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..29) 471
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..30) 472
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..31) 473
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..32) 474
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..33) 475
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..34) 476
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..35) 477
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..36) 478
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..37) 479
Gastrointestinal Tract Cancer Therapeutics – Dormant Products (Contd..38) 480
List of Figures
Number of Products under Development for Gastrointestinal Tract Cancer, H2 2012 25
Products under Development for Gastrointestinal Tract Cancer – Comparative Analysis, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 41
Late Stage Products, H2 2012 60
Mid Clinical Stage Products, H2 2012 61
Early Clinical Stage Products, H2 2012 62
Discovery and Pre-Clinical Stage Products, H2 2012 63
Assessment by Monotherapy Products, H2 2012 287
Assessment by Combination Products, H2 2012 288
Assessment by Route of Administration, H2 2012 289
Assessment by Stage and Route of Administration, H2 2012 290
Assessment by Molecule Type, H2 2012 291
Assessment by Stage and Molecule Type, H2 2012 292

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2245278/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Gastrointestinal Tract Cancer - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2245278/
Office Code: SCD2STDH

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr [ ]</th>
<th>Mrs [ ]</th>
<th>Dr [ ]</th>
<th>Miss [ ]</th>
<th>Ms [ ]</th>
<th>Prof [ ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td>Last Name:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World